Results 181 to 190 of about 186,731 (268)

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Development and Validation of a Traditional Chinese Medicine Constitution-Based Risk Score for Advanced Colorectal Neoplasia in Asymptomatic Chinese Adults. [PDF]

Cancer Manag Res
Huang C, Hou Y, Liu QH, Kang Q, Fan YJ, Zhu LQ, Sun L, Men RC, Li XY, Gu YL, Ni Q, Wang H, He Y.   +12 more
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Revisiting Light's criteria: a validated blood-free triple combination matches diagnostic accuracy in over 7000 patients. [PDF]

ERJ Open Res
Porcel JM, Porcel L, Palma R, Bielsa S.
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Correction for Scherrer et al., Characterizing sliding and rolling contacts between single particles. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Patient-specific trophoblast stem cells for placental medicine. [PDF]

Trends Mol Med
Kim SW, Genceroglu A, Kim J.
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Investigation of the lower block rows in the King's Chamber of the Great Pyramid using ultrasonic testing with shear wave arrays. [PDF]

Sci Rep
Maier B, Hamza AG, Ramirez-Pinero A, Taie K, Schumacher T, Popovych O, Elkarmoty M, Tayoubi M, Helal H, Grosse CU.   +9 more
europepmc   +1 more source